Creative Medical Technology Holdings Inc.'s Immcelz (CELZ-101) has been awarded orphan drug designation by the FDA. Immcelz is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation.
Neuraminidase (NA) is an essential surface protein of influenza viruses with potential as an effective drug and vaccine target. However, knowledge of the NA antigenic landscape remains limited, and most current influenza vaccines induce antibodies against the surface glycoprotein hemagglutinin.
In a recent study published in PNAS, researchers from the University of Texas Southwestern Medical Center investigated cholesterol-mimetic compounds specifically binding and inhibiting Scap. Their final goal was to understand cholesterol regulation by the Scap/SREBP system and identify potential therapeutics for dysregulated lipid metabolism.
China State Institute of Pharmaceutical Industry and Jiangsu Nhwa Pharmaceutical Co. Ltd. have jointly described aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivatives acting as serotonin 5-HT1A and/or dopamine D2 and/or D3 receptor agonists reported to be useful for the treatment of Parkinson’s disease.
Nuvalent Inc. has disclosed new heteroaromatic macrocyclic ether compounds acting as proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.
Bristol Myers Squibb Co. has identified tetrazole derivatives acting as diacylglycerol kinase α (DGK-α; DGKA) and/or diacylglycerol kinase ζ (DGK-ζ; DGKZ) inhibitors reported to be useful for the treatment of cancer and viral infections.